NDA 021764 · Sandoz
Qoliana
Brimonidine Tartrate · Ophthalmic
Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
May 22, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
177
44 Phase 3, 5 recruiting
FAERS reports
3,396
1,716 serious, 189 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 24, 2025.
Brimonidine tartrate ophthalmic solution, 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Brimonidine tartrate ophthalmic solution, 0.15% is an alpha adrenergic agonist indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension ( 1 ).
Mechanism: Brimonidine tartrate ophthalmic solution, 0.15% is an alpha-2 adrenergic receptor agonist. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- QOLIANA · BRIMONIDINE TARTRATE 0.15% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Brimonidine" as an intervention, any sponsor and status, largest first.
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01309204 · 1,184 participants · Start May 2011 · Primary completion Jan 2013
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension; Vehicle and 2 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01297920 · 1,062 participants · Start Mar 2011 · Primary completion Jun 2012
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1% and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01297517 · 1,001 participants · Start Feb 2011 · Primary completion Mar 2012
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1% and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01310777 · 771 participants · Start May 2011 · Primary completion Jan 2013
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide 1% ophthalmic suspension and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Evaluation of Safety and Efficacy of PDP-716Pivotal-lookingCompleted
Sun Pharma Advanced Research Company LimitedIndustry
NCT03450629 · 682 participants · Start Sep 13, 2018 · Primary completion Dec 1, 2020
Drug: Brimonidine Tartrate Ophthalmic Suspension; Brimonidine Tartrate Ophthalmic Solution · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Chandler, Arizona; Prescott, Arizona; Sun City, Arizona · 47 sites in all
- Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic PresbyopiaPivotal-lookingCompleted
Visus TherapeuticsAcademic, hospital or other
NCT05135286 · 629 participants · Start Mar 15, 2022 · Primary completion Mar 13, 2025
Drug: BRIMOCHOL™ PF; Carbachol PF and 1 more · For: Presbyopia
Sites: Chandler, Arizona; Phoenix, Arizona; Sun City, Arizona · 42 sites in all
- Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension PatientsPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00651612 · 604 participants · Start Nov 2005 · Primary completion Jan 2007
Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution; Concurrent brimonidine 0.2% and 0.5% timolol · For: Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00332436 · 586 participants · Start Dec 1999 · Primary completion Nov 2001
Drug: brimonidine/timolol fixed combination · For: Ocular Hypertension
Sites: Louisville, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye pain288
- eye irritation218
- product use issue194
- fatigue185
- drug ineffective180
- headache169
- ocular hyperaemia164
- vision blurred164
- dizziness146
- product dose omission issue127
- death119
- off label use116
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 39 |
| 2006 | 36 |
| 2007 | 53 |
| 2008 | 37 |
| 2009 | 45 |
| 2010 | 55 |
| 2011 | 81 |
| 2012 | 77 |
| 2013 | 44 |
| 2014 | 52 |
| 2015 | 93 |
| 2016 | 109 |
| 2017 | 112 |
| 2018 | 146 |
| 2019 | 159 |
| 2020 | 275 |
| 2021 | 213 |
| 2022 | 245 |
| 2023 | 291 |
| 2024 | 323 |
| 2025 | 376 |
| 2026 | 507 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Post-acne erythema treatment: A systematic review of the literature.
Kalantari Y, Dadkhahfar S, Etesami I · J Cosmet Dermatol 2022 · Systematic Review
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
van Zuuren EJ, Fedorowicz Z, Tan J, et al. · Br J Dermatol 2019 · Systematic Review
- Interventions for rosacea.
van Zuuren EJ, Fedorowicz Z, Carter B, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Neuroprotection for treatment of glaucoma in adults.
Sena DF, Lindsley K · Cochrane Database Syst Rev 2017 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.